Abstract
Radical treatment of the entire prostate gland is still the standard of care for high-risk PCa. However, focal HIFU ablation is a safe procedure and has shown promising short-term oncological outcomes, with acceptable complication rate and excellent functional outcomes. Prospective studies with long-term follow-up are needed to determine the true role of focal HIFU for PCa. Until then, focal HIFU should be offered only in the setting of clinical trials, particularly for high-risk PCa.